drugset / Trial / NCT00112749

Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer

NCT00112749

NaSingle-groupOpen-labelSupportive care

Summary

RATIONALE: Infliximab may help improve energy levels in patients who have undergone treatment for breast cancer. PURPOSE: This phase II trial is studying how well infliximab works in treating cancer-related fatigue in postmenopausal women who have undergone treatment for stage 0, stage I, or stage II breast cancer.

Timeline

Start
2005-02
Primary completion
2007-01
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody 1 mg/kg Intravenous

Indications